Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein Barr Virus Associated Diseases (EBVision)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04554914
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:23.263247+00:00
Published At
2026-02-20T00:00:00+00:00
Record Updated At
2026-02-20
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Epstein-Barr Virus (EBV)-Associated Diseases", "EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)", "EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)", "EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)", "EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD)", "Solid Organ Transplant Complications", "Lymphoproliferative Disorders", "Allogeneic Hematopoietic Cell Transplant", "Stem Cell Transplant Complications", "EBV+ Sarcomas", "Leiomyosarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-20"
protocolSection.identificationModule.nctId
"NCT04554914"
protocolSection.identificationModule.officialTitle
"An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein Barr Virus Associated Diseases (EBVision)"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Epstein-Barr Virus (EBV)-Associated Diseases (protocolSection.conditionsModule.conditions)
  • EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD) (protocolSection.conditionsModule.conditions)
  • EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD) (protocolSection.conditionsModule.conditions)
  • EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD) (protocolSection.conditionsModule.conditions)
  • EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD) (protocolSection.conditionsModule.conditions)
  • Solid Organ Transplant Complications (protocolSection.conditionsModule.conditions)
  • Lymphoproliferative Disorders (protocolSection.conditionsModule.conditions)
  • Allogeneic Hematopoietic Cell Transplant (protocolSection.conditionsModule.conditions)
  • Stem Cell Transplant Complications (protocolSection.conditionsModule.conditions)
  • EBV+ Sarcomas (protocolSection.conditionsModule.conditions)
  • Leiomyosarcoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.